Skip to content
Back to announcement

20260325_RSGK_Public Expose_32055129_lamp3.pdf

Other Text extracted RSGK

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 27

Page 1
     PUBLIC EXPOSE
PT KEDOYA ADYARAYA TBK
     Jakarta, 25 March 2026
Page 2
                                                                                                             Disclaimer


This presentation has been prepared by PT Kedoya Adyaraya Tbk (“RSGK”) as a general overview of the Company’s condition
and performance. The information contained herein does not constitute investment advice, an offer to buy or sell securities, or
any financial recommendation. It does not take into account the specific objectives, financial situation, or needs of any
particular party.

This presentation may contain forward-looking statements that reflect management’s current expectations regarding future
events, business performance, and financial conditions. These statements involve risks and uncertainties that may cause actual
results to differ materially from those expressed or implied. Past performance is not necessarily indicative of future results, and
RSGK undertakes no obligation to update any forward-looking statements.

The consolidated financial information presented, including the financial position as of 31 December 2025, has been prepared
in accordance with Indonesian Financial Accounting Standards (PSAK) and has been audited by an independent auditor.

While reasonable care has been taken in preparing this presentation, RSGK make no representation or warranty, express or
implied, as to the accuracy or completeness of the information contained herein and accept no liability for any loss arising from
reliance on this presentation.




                                                    150789   021 2977 9977   www.grhakedoya.com                                       2
Page 3
  01          02            03
Company    Strategic     Financial
Overview   Initiatives   Performance
                         Review
Page 4
Company Overview
Page 5
                                                                                                                     Milestones

                                                                                                     • Rebranding EMC Grha Kedoya
                                                                                                       Hospital
                                                                        • 2nd JCI Accreditation      • Signing MOU with Siemens
                                                                        • Rebranding EMC               Healthineers for Biograph
               Grand Opening                Grha Kedoya                   Cibitung Hospital            Vision Quadra PET/CT
             Grha Kedoya Hospital   Hospital has JCI accreditation




                  2011                       2019                               2022                      2024
     1990                      2018                         2021                                2023                  2025

Company Establishment                                    IPO of PT Kedoya            • Grand Launching Lexo &       • Grand Launching Biograph
                           MM2100 Hospital                 Adyaraya Tbk                Diego                          Vision Quadra PET/CT
                             Acquicition                                             • TrakCare Intersystem         • EMRAM Stage 6
                                                                                       Implementation               • 3rd JCI Accreditation
                                                                                                                    • Transforming into an AI-
                                                                                                                      powered hospital group,
                                                                                                                      supported by the
                                                                                                                      implementation of
                                                                                                                      InterSystems IntelliCare and
                                                                                                                      a fully integrated Hospital
                                                                                                                      Information System (HIS)
                                                                                                                      across all units

                                                       150789   021 2977 9977   www.grhakedoya.com                                                   5
Page 6
Board of Commissioners




     JUSUP HALIMI            dr. LIEM KIAN HONG                 HUNGKANG SUTEDJA                          MURNIADI CHANDRA          dr. YANTO SANDY TJANG
President Commissioner   Vice President Commissioner              Commissioner                         Independent Commissioner   Independent Commissioner




                                                       150789     021 2977 9977   www.grhakedoya.com                                                     6
Page 7
Board of Directors




 dr. JUNIWATI GUNAWAN     HENDRA MUNANTO                          ARMEN ANTONIUS DJAN   drg. NAILUFAR
     President Director       Director                                  Director           Director




                                   150789   021 2977 9977   www.grhakedoya.com                          7
Page 8
                         VISION

EMC aspires to provide the most trusted and
accessible healthcare for the advancement of the
nation's healthcare quality.




                           MISION
   • Putting patients' needs and safety as our utmost priority
   • Promoting culture of continuous learning and innovation
   • Building healthcare centers of excellence
     with international standard quality



                        VALUES


    Empathy               Meaningful           Competence
        &                     &                     &
    Integrity              Respect              Innovation

                                                             8
Page 9
                                                                       Group Structure & Shareholders


                                                              13,13%                            77,31%                  7,55%




                                                              99,00%                            99,66%                  99,50%




                                                                                                99,00%

Note : As of 13 March 2026 the Company’s Free Float shares
       amount to 70,160,846 shares or representing 7.55% of
       the total registered shares. The Company has comply
       with provision V.1.1 IDX Regulation Number I-A



                                                                       150789   021 2977 9977      www.grhakedoya.com            9
Page 10
                                              Operational Area




150789   021 2977 9977   www.grhakedoya.com                  10
Page 11
                                                                             Profile of the Hospitals




    Bed             Operating theatre
                                                                     Bed                  Operating theatre

 200                       4                                      120                            4


Specialist Doctor      Medical Staff
                                                                 Specialist Doctor            Medical Staff

  128                   368                                          40                         167



                                        150789   021 2977 9977       www.grhakedoya.com                       11
Page 12
                                                                                           Awards & Certificates




     (1)                           (2)                               (3)                                 (4)                                (5)


(1) KARS Accreditation Certificate No. KARS-                                   (4) Global Health Award for Advanced PET/CT
    SERT/103/IX/2022 year 2022-2026 – EMC Cibitung Hospital                    (5) Validation of Electronic Medical Record Adoption Model
(2) KARS Accreditation Certificate No. KARSSERT/1487/VII/                         (EMRAM) Stage 6, HIMSS, year 2025-2028
    2024 year 2024-2028 – EMC Grha Kedoya Hospital
(3) JCI Accreditation, year 2025-2028


                                                      150789   021 2977 9977      www.grhakedoya.com                                              12
Page 13
Strategic Initiatives
Page 14
  EMC
Healthcare
  Strategic
Development
   Plan




              150789   021 2977 9977   www.grhakedoya.com   14
Page 15
                          Strategic Development Plan




150789   021 2977 9977   www.grhakedoya.com       15
Page 16
                                                                 Biograph Vision Quadra PET/CT Scanner
                                                                           at EMC Grha Kedoya Hospital

Latest Technology & First in Asia:
Using Biograph Vision Quadra, a leading-edge true
whole-body PET/CT scan that sets a new standard in
cancer diagnostics.

Ultra-Fast Scan Time:
A full-body (head-to-toe) scan takes only about 4
minutes, increasing patient comfort and reducing
anxiety.

High Resolution and Sensitivity:
Capable of detecting cancer cells or very small
abnormalities at the molecular level, even before
they are visible on conventional CT or MRI scans.

Lower Radiation:
The radiation dose is 50% to 75% lower than
standard PET/CT technology, making it safer for
patients, including for long-term monitoring or
pediatric patients.

106 cm Scanning Area:
The axial field of view reaches 106 cm, enabling
scanning of a large body area in a single session.




                                                     150789   021 2977 9977   www.grhakedoya.com    16
Page 17
            AI Innovation and Patient’s Portal
                            Transition to a Fully AI-Driven Hospital Network




150789   021 2977 9977   www.grhakedoya.com                                    17
Page 18
Peningkatan Keamanan Data




 HIS (Intellicare)




                                                     13
       150789   021 2977 9977   www.grhakedoya.com    18
Page 19
                    Data Security Enhancement




150789   021 2977 9977   www.grhakedoya.com   19
Page 20
Collaborations and Strategic Initiatives




  150789   021 2977 9977   www.grhakedoya.com   20
Page 21
Collaborations and Strategic Initiatives




  150789   021 2977 9977   www.grhakedoya.com   21
Page 22
                                              CSR Program 2025




150789   021 2977 9977   www.grhakedoya.com                      22
Page 23
Financial Performance Review
Page 24
                                                                     Statement of Profit or Loss
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025 AND 31 DECEMBER 2024

                                                                                     Year Ending on Date                   Increase
                         Information
                                                                                  2025                    2024            (Decrease)
   Revenues                                                                  469,592,692,612         441,072,473,575          6%
   Cost of Revenues                                                         (321,943,527,923)       (291,749,619,707)         10%
   Gross Profit                                                              147,649,164,689         149,322,853,868          -1%
   Operating Expenses                                                       (103,623,384,809)         (97,735,863,928)        6%
   Other Income - net                                                            3,443,228,705           3,438,709,855        0%
   Operating Income                                                            47,469,008,585          55,025,699,795        -14%
   Finance income                                                                5,021,372,545           4,029,482,807        25%
   Finance costs and Bank administration                                        (7,250,660,746)         (2,346,862,454)      209%
   Profit before income tax                                                    45,239,720,384          56,708,320,148        -20%
   Income tax expenses - net                                                  (10,773,400,741)        (17,110,463,907)       -37%
   Profit for the year                                                         34,466,319,643          39,597,856,241        -13%
   Other comprehensive income                                                   (3,343,352,721)        17,838,297,170       -119%
   Total other comprehensive income for the year                               31,122,966,922          57,436,153,411        -46%
   Profit for the year attributable to:
     Owners of the parent entity                                              34,507,058,537          39,692,367,036        -13%
     Non-controlling interest                                                    (40,738,894)            (94,510,795)       -57%


                                                   150789   021 2977 9977     www.grhakedoya.com                                       24
Page 25
                                               Statement of Financial Position

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 31 DECEMBER 2025 AND 31 DECEMBER 2024

                                                                    31 December            31 December         Increase
                           Information
                                                                        2025                   2024           (Decrease)
   Assets
   Total Current Asset                                                127,217,813,363       127,236,246,527      0%
   Non-Current Assets                                                 956,294,891,815       760,391,336,488      26%
   Total Assets                                                     1,083,512,705,178       887,627,583,015      22%

   Liabilities
   Non-current Liabilities                                           126,984,370,099         69,654,225,302      82%
   Total Non-current Liabilities                                     126,759,253,678         19,512,451,817     550%
   Total Liabilities                                                 253,743,623,777         89,166,677,119     185%

   Equity
   Equity attributable to
     owners of the parent entity                                     828,793,492,478        797,669,220,072      4%
   Non-controlling interest                                              975,588,923            791,685,824      23%
   Total Equity                                                      829,769,081,401        798,460,905,896      4%



                                           150789   021 2977 9977     www.grhakedoya.com                                   25
Page 26
                                                                             Statement of Cash Flows


CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025 AND 31 DECEMBER 2024

                                                                             31 Decmber           31 December          Increase
                           Information
                                                                                2025                  2024            (Decrease)
   Cash flows from operating activities                                       90,246,003,649       81,804,569,371        10%
   Cash flows from investing activities                                      (90,240,253,768)      (74,604,778,093)      21%
   Cash flows from financing activities                                         6,956,797,596      (10,226,425,000)     168%
   Net increase/(decrease) in cash on hand and in Banks                        6,962,547,477        (3,026,633,722)     330%
   Cash on hand and in Banks at beginning of year                             54,397,160,838       57,423,794,560        -5%
   Cash on hand and in Banks at end of year                                   61,359,708,315       54,397,160,838        13%




                                                    150789   021 2977 9977   www.grhakedoya.com                                    26
Page 27

          

File

File Open PDF
Source IDX
Size6.32 MB
Published25 Mar 2026
Pages27
Characters16,757
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 13 people and organisations named in the text · linked when the evidence is strong

linked org KEDOYA ADYARAYA TBK p.1 ×5
linked person JUSUP HALIMI p.6
linked person dr. LIEM KIAN HONG p.6
linked person HUNGKANG SUTEDJA p.6
linked person MURNIADI CHANDRA p.6
linked person dr. YANTO SANDY TJANG p.6
linked person dr. JUNIWATI GUNAWAN p.7
linked person HENDRA MUNANTO p.7
linked person ARMEN ANTONIUS DJAN p.7
possible person drg. NAILUFAR p.7
unresolved org PT Kedoya p.5
unresolved org Adyaraya Tbk p.5
unresolved person Vice · President Commissioner p.6 ×2

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

↑↓ select ↵ open ⇧↵ see every result